威高股份(01066.HK)擬8470萬元購買威海弘陽瑞信息技術中心28.57%股份
格隆匯5月21日丨威高股份(01066.HK)發佈公告,於2020年5月21日,公司全資附屬威高信達擬向賣方弓劍波先生購買威海弘陽瑞信息技術中心(有限合夥)28.57%股份,代價約為人民幣8470萬元。
有限合夥企業為一家持有23,333,333股骨科股份的有限合夥企業,相當於威高骨科6.51%股份。其主要從事銷售電子產品及研發電腦硬件及軟件。威高骨科主要從事製造骨科醫療器械產品。
公司稱,收購事項乃為嘉許弓先生過去領導威高骨科成為行業內占主導地位的參與者之一、擴大威高骨科產品線及威高骨科增長所作出的貢獻。威高骨科為集團的核心業務分部之一。於威高骨科的權益增加將進一步加強集團的盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.